CN1121869C - 正糖胶囊 - Google Patents
正糖胶囊 Download PDFInfo
- Publication number
- CN1121869C CN1121869C CN 01115232 CN01115232A CN1121869C CN 1121869 C CN1121869 C CN 1121869C CN 01115232 CN01115232 CN 01115232 CN 01115232 A CN01115232 A CN 01115232A CN 1121869 C CN1121869 C CN 1121869C
- Authority
- CN
- China
- Prior art keywords
- parts
- capsule
- zhengtang
- fructus
- treating diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 23
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 42
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 6
- 241000190633 Cordyceps Species 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 239000008517 radix Trichosanthis Substances 0.000 claims description 10
- 241000219295 Portulaca Species 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 6
- 241000600871 Euryale <brittle star> Species 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 5
- 210000000952 spleen Anatomy 0.000 abstract description 4
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 230000006820 DNA synthesis Effects 0.000 abstract 1
- 244000268590 Euryale ferox Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 244000234609 Portulaca oleracea Species 0.000 abstract 1
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 229940109850 royal jelly Drugs 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000000378 dietary effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000010242 baoji Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 241001480006 Clavicipitaceae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- PMUIBVMKQVKHBE-UHFFFAOYSA-N [S].NC(N)=O Chemical compound [S].NC(N)=O PMUIBVMKQVKHBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002478 diastatic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000005205 dihydroxybenzenes Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- -1 monoterpene glycosides Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 229930192961 schisandrol Natural products 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
一种治疗糖尿病的正糖胶囊,属于食疗中药复方制剂。其原料组成及重量份数比是:薯蓣10-15 马齿苋10-15 王瓜籽10-12 芡实7-10 荷叶8-10 虫草0.1-0.3 天花粉10-15 五味子8-16 黄精10-12 黄芪10-15 西洋参0.3-0.5 枸杞15-17。它采用标本兼治原则,可纠正人体糖、蛋白质、脂肪代谢的失调与紊乱,实现三治及调节肝脾胃肾等功能,促进DNA合成,增加人体胰腺细胞的复活率与新生。本发明长期服用无毒副作用,经对820例患者临床观察优于服用其它药物对照组,有效率达92%。
Description
本发明涉及一种治疗糖尿病的正糖胶囊,属于中成食疗药品制造技术领域。
当前,国内外用于治疗糖尿病的药物仍是以口服的西药为主。在诸多的降糖西药药品中,通常分别是磺脲类、双胍类、α-葡萄糖苷酶抑制剂三种化学品的衍生物。如:甲糖宁、氯磺丙脲、优降糖、糖威胶囊等是以磺脲为基础的;降糖灵、二甲双胍、立克糖、美迪康等是以双胍为基础的;致于α-葡萄糖苷酶抑制剂只不过使人体对各种糖延缓吸收而已。这些纯化学药物的致命缺陷是对人体毒副作用大,它刺激患者的肝、肾、心、脑,使患者的综合体质下降;同时部分患者还存在原发性或继发性药物失效的隐患。鉴于上述口服西药的缺憾,中国医疗界治疗糖尿病目前开始向中医中药、食疗偏移。经中国专利文献检索得知,以各种中药原料为主的降糖药物专利申请已有报导,但品种少,且选料局限性大,故疗效不尽人意。特别是以中药原料和其以外的菜蔬、种籽等为主基料而配制的降糖食疗中成药品尚不多见。
本发明的目的在于针对上述背景技术的不足而推出一种标本兼治,长期服用对人体无毒副作用,综合降糖治疗效果好的正糖胶囊。
实现本发明的目的需采用以下实施方案:即这种治疗糖尿病的正糖胶囊,其原料组成及重量份数比是:薯蓣10-15马齿苋10-15王瓜籽10-12芡实7-10荷叶8-10虫草0.1-0.3天花粉10-15五味子8-16黄精10-12黄芪10-15西洋参0.3-0.5枸杞15-17。具体地说,在实际生产制作中所采用的原料组成及重量份数比可以是:薯蓣10马齿苋10王瓜籽10芡实7荷叶8虫草0.1天花粉10五味子8黄精10黄芪10西洋参0.3枸杞15。也可以是:薯蓣13马齿苋13王瓜籽11芡实9荷叶9虫草0.2天花粉13五味子12黄精11黄芪12西洋参0.4枸杞16。还可以是:薯蓣15马齿苋15王瓜籽12芡实10荷叶10虫草0.3天花粉15五味子16黄精12黄芪15西洋参0.5枸杞17。
本发明的优点是:第一、原料选用科学严谨,对症性强。如:针对糖尿病人多皆气阴两亏、肾虚、性衰遗精等症而选用富含多种五味子素与五味子醇、挥发油、有机酸及维生素A的五味子,以养五脏、敛肺滋肾、养心益气。针对糖尿病人口渴、多饮、尿频等症,选用富含二羟基苯乙胺、丙胺及含维生素类有机酸的马齿苋(俗称马齿菜)和含花粉蛋白、多种氨基酸、皂甙的天花粉,以凉血、清热解毒、消除病人唇舌干燥、口渴之症,并可取得抑制消谷善饥的效果。针对糖尿病人多缺蛋白及氨基酸,选用富含皂甙粘液蛋白、尿囊素、精氨酸、胆碱、淀粉酶的薯蓣滋补患者脾胃肾。用料中虫草为麦角菌科真菌,含粗蛋白25%,水解产物是谷氨酸,脯氨酸等多种氨基酸混合物,它含脂肪8.4%、D甘露醇、维生素B120.29μg/100g、尿嘧啶等,用于补充患者体能。其成份中的甘露醇可降脑压,以消解糖尿病人的合并症;维生素B12可养肝;尿嘧啶与肾有益,可补肾补肺,抑制患者可能发生的其它各种并发症。针对糖尿病人有1/3-1/4的人血脂高、血压高,不少人动脉硬化,选用黄芪扩血管、降血压,以补心脑缺血、强心利尿。王瓜籽是借民间治疗糖尿病有大效的佳传而选。西洋参的根含总皂甙0.4-1.3%,以人参皂甙Rb为主,不含Rg1,用它可补气养阴、清火生津、以消除糖尿病人身倦体乏、无力,双腿发软之症状。致于芡实,富含多种维生素及PO4、Ca、Fe成分,加上荷叶,均为加强综合疗效的有效原料。第二、标本兼治,调整机体内脏的生理功能达到降低血糖、尿糖、修复胰腺的目的,且对人体无毒副作用,综合治疗效果好。由于本发明中的诸原料药均属食疗范围的食疗药品,固长期服用对人体无任何毒副反应。同时各味药之间皆有协同互补作用,在不损害患者整体素质的基础上平稳治疗疾病。如黄芪、西洋参、虫草均为补虚劳之药物,有相辅相承的作用,而芡实、薯蓣为补脾胃之要药,二者相协调,即不泄泻又防便秘,互为补益。王瓜籽、马齿苋除药书记载外又是民间验方,皆为蔬菜。加上五味子、荷叶、花粉等协同作用,有良好的降糖治疗效果。经十年来对820例患者临床应用观察,疗效优于服用其它药物的对照组,有效率达92%。
本发明的药理作用是:由于配方中含有多种氨基酸和能为机体直接吸收的Ca、Mg、Mn、Cr、Si、Fe、Zn等元素,以及各种挥发油、维生素、β-谷甾醇、单萜苷、生物碱、花粉蛋白、腺嘌呤等成分,而人体这些成分的缺少,便可导致糖尿病(国内外已有这方面的论文发表),故补充上述各种成分作用于整个人体各个部位及系统媒体与神经介质之间,再配合其它药物治疗,达到整体治疗之目的。它可以纠正人体糖、蛋白质、脂肪代谢的失调与紊乱,降血糖、血脂、血压,调节肝脾胃肾等功能,促进DNA的合成,排除胰岛素受体的封闭与被干扰,增加人体胰腺细胞的复活率与新生。具有补中益气、滋补肝肾、降糖止渴、益精明目、气阴双补、补脾益胃的综合疗效。达到从根本上治病,而不是单纯降糖。
本发明的生产制作是采用传统的制作方法,即将所选用的各种原料分别精选、过筛、烘乾、粉碎后消毒装入胶囊而成。临床实践中,根据患者病症的不同表现,轻重程度选用适合的正糖胶囊。在每份原料重量相同的条件下,例举下列三组正糖胶囊:
第一组 第二组 第三组
薯蓣 10 13 15
马齿苋 10 13 15
王瓜籽 10 11 12
芡实 7 9 10
荷叶 8 9 10
虫草 0.1 0.2 0.3
天花粉 10 13 15
五味子 8 12 16
黄精 10 11 12
黄芪 10 12 15
西洋参 0.3 0.4 0.5
枸杞 15 16 17
下边结合病案进一步详述实施例:
例一:李天才,男,44岁,农行公务员
1994年因糖尿病来我研究所求治,糖尿病史当时已6年,外观体质极瘦,有弱不经风的样子,当时由左右两个人扶持走入诊室,病人萎钝,精神不振,语慢懒言,自觉无力,全身麻痛,由头顶至足尖有如电击样一次又一次发作,彻夜不能入睡,晨查血糖28.6mmoi/L,尿糖(++++)尿八项中G/ucose(++++)PH 6 protein(-)
诊断为:①II型糖尿病(进展期)重型
②糖尿病性神经炎
治疗原则:1、服用正糖胶囊(第三组),用法:每日三次每次四粒,饭
前服;
2、VB1
VB12
谷维素用法:每日三次每次两片,饭后服;
3、中药治疗(饮片)(治疗合并症)
4、穴位封闭,血管内药物封闭。
预后,治疗三个月后血糖恢复到5.6mmoi/L尿糖(一),神精炎好了,没有麻痛发作了,精神状态好了,体力恢复了,又上班断续工作了。目前仍继续服用正糖胶囊(第三组)。
例二:王敏,68岁,女,退休职工
主诉,8年前患糖尿病,于95年来研究所治疗,曾口服达美康、消渴丸、D860等药物,效果不佳,来我所求治,自觉无力,有时头晕。
检查:精神尚好,言语清析,BP145/85mmHg
晨血糖16mmoi/L,尿八项中G/ucose(++++)
尿蛋白(++)PH7
余正常
诊断:①II型糖尿病(中型)
②糖尿病性蛋白尿(合并症)
处置1、正糖胶囊(第二组)用法:每日三次每次四粒,饭前服;
预后,患者连续服药,加强体育疗法与控制饮食,制定合理饮食制度及心理治疗。经二个月治疗后,早晨空服查血糖为5mmoi/L,尿糖(-),蛋白尿由原本的(++)减为(±),病人自觉体力恢复,心情也愉快,现在已是68岁的老人,还能去公园跳舞、慢步活动、家务劳动,现在每日服药维持身体健康,她达到了我们治疗糖尿病的临床治愈标准(五项标准):
即(1)血糖值恢复正常
(2)尿糖阴性
(3)体力恢复照常工作
(4)症状消失,很少得合并症
(5)精神旺盛,恢复良好
例三:骆秉来,男,60岁,宝鸡市纪检委书记
病人来诊是在96年,当时得病2-3年,口服多种药品效果不著,来我所求医,当时自觉无力,有三多一少症状。检查,晨血糖13.2mmoi/L,饭后二小时血糖17mmoi/L,BP145/90mmHg,脉宏弦,尿糖(++++)体重轻。
诊断(1)II型糖尿病
(2)高血压倾向
处置:正糖胶囊(第三组)用法:每日三次每次四粒,饭前服;
预后:病人由96年到2001年连续服正糖胶囊(第三组),从不间断,血糖在治疗的一个月后即降到6.1mmoi/L-4mmoi/L,以后从不上升,精神好,体力恢复,退休后在外地(西安)服务,按时来所取药,高血压也得到控制,不上升。达到了治疗的五项标准。
例4:高端武,男,63岁,宝鸡市纪检委副书记
96年病人来所求治,当时有头晕,血压高,患糖尿病3年,体力不佳,外出需人护理。
检查:血糖13.6mmoi/L,尿糖(+++),尿八项正常。
诊断:II型糖尿病
处置:正糖胶囊(第一组)用法:每日三次每次四粒,饭前服;
预后:病人连续服药,一个月后血糖降到4.8mmoi/L,以后多次检测,从无上升,一直在3.8-6.1之间,目前病人自觉好转,体力好了,退休后连续工作,正糖胶囊由每日次4丸减少到三丸,每日三次减少为每日二次,血糖尿糖仍然为正常标准,达到了治疗的五项标准。
Claims (4)
1、一种治疗糖尿病的正糖胶囊,其特征在于:其原料组成及重量份数比是:
薯蓣 10-15 马齿苋 10-15 王瓜籽 10-12 芡实 7-10
荷叶 8-10 虫草 0.1-0.3 天花粉 10-15 五味子 8-16
黄精 10-12 黄芪 10-15 西洋参 0.3-0.5 枸杞 15-17。
2、根据权利要求1所述的正糖胶囊,其特征在于:正糖胶囊的原料组成及重量份数比是:
薯蓣 10 马齿苋 10 王瓜籽 10 芡实 7
荷叶 8 虫草 0.1 天花粉 10 五味子 8
黄精 10 黄芪 10 西洋参 0.3 枸杞 15。
3、根据权利要求1所述的正糖胶囊,其特征在于:正糖胶囊的原料组成及重量份数比是:
薯蓣 13 马齿苋 13 王瓜籽 11 芡实 9
荷叶 9 虫草 0.2 天花粉 13 五味子 12
黄精 11 黄芪 12 西洋参 0.4 枸杞 16。
4、根据权利要求1所述的正糖胶囊,其特征在于:正糖胶囊的原料组成及重量份数比是:
薯蓣 15 马齿苋 15 王瓜籽 12 芡实 10
荷叶 10 虫草 0.3 天花粉 15 五味子 16
黄精 12 黄芪 15 西洋参 0.5 枸杞 17。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01115232 CN1121869C (zh) | 2001-04-24 | 2001-04-24 | 正糖胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01115232 CN1121869C (zh) | 2001-04-24 | 2001-04-24 | 正糖胶囊 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1322563A CN1322563A (zh) | 2001-11-21 |
CN1121869C true CN1121869C (zh) | 2003-09-24 |
Family
ID=4661809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 01115232 Expired - Fee Related CN1121869C (zh) | 2001-04-24 | 2001-04-24 | 正糖胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1121869C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102599511B (zh) * | 2012-03-23 | 2013-10-09 | 南宁市品迪生物工程有限公司 | 一种治疗糖尿病的食疗配方 |
CN105998089B (zh) * | 2016-07-05 | 2020-07-21 | 青海珠峰冬虫夏草工程技术研究有限公司 | 冬虫夏草在制备预防和/或治疗胰腺纤维化的药物中的应用 |
-
2001
- 2001-04-24 CN CN 01115232 patent/CN1121869C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1322563A (zh) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100374140C (zh) | 一种用于糖尿病的保健品 | |
CN102526478B (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN102526479B (zh) | 一种增强免疫力、降血糖功能的保健药物 | |
CN102366595A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN108524673A (zh) | 一种中药组合物及其应用 | |
CN1895547A (zh) | 一种治疗糖尿病的药物及制备方法 | |
CN1879802A (zh) | 补肝肾抗衰老降三高营养中药品及制备方法 | |
CN1121869C (zh) | 正糖胶囊 | |
CN102274396B (zh) | 治疗糖尿病肾病的中药及其制备方法 | |
CN1768838A (zh) | 一种促进排铅的中药制剂及其制备方法 | |
KR102198434B1 (ko) | 천연식물을 이용한 고지혈증 예방 또는 치료용 약학 조성물, 그 제조방법 및 제제 | |
CN103393938B (zh) | 一种降血糖的中药组合物 | |
CN102552677B (zh) | 黄地安消胶囊及其制备方法 | |
CN1107711A (zh) | 复方降糖胶囊 | |
CN101537102A (zh) | 一种治疗糖尿病的药食两用组合物及其制备方法 | |
CN100339119C (zh) | 一种治疗糖尿病的降糖中药制剂 | |
CN1285367C (zh) | 一种治疗糖尿病的药物制剂及其制备方法 | |
CN106606744A (zh) | 一种用于治疗ⅱ型糖尿病的组合药物 | |
CN102366540A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN1768778A (zh) | 决明子在制备促进排铅作用药品或保健品中的应用 | |
CN1234266A (zh) | 复胰糖脂平 | |
CN1287836C (zh) | 治疗糖尿病的中药颗粒及生产方法 | |
CN1274339C (zh) | 氨杞制剂及其制备方法和用途 | |
CN1864728A (zh) | 参黄养阴胶囊的处方和制法 | |
CN1435209A (zh) | 治疗糖尿病的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |